The company's Curian immunoassay instrument is currently in front of the FDA, and the PediaStat will likely be submitted later this year.
To market its analyte specific reagents, syndromic enteric panels, and other tests, the firm is building a US-based sales organization.
The firm said its panel, which runs on its MDx-3000 system, tests nasopharyngeal swabs for the most common viruses and bacteria.
The firm said that its newly CE-marked test for intestinal infections is suitable for use in laboratories and hospitals, and provides results in 90 minutes.
The FDA-cleared panel includes tests for salmonella, Shiga toxin-producing Escherichia coli, Shigella, Campylobacter, and Cryptosporidium.
Progenity gains 137 granted patents and 15 pending applications in the US, Europe, China, and Japan in the deal.
The San Francisco-based microbial genomics firm will sell off its product lines, testing labs, IP, and data within the next three months.
Nestlé Health said that employees of Prometheus are becoming employees of Precision IBD, with the exception of those working in its point-of-care diagnostic business.
Israel-based software company Medial EarlySign will work with Geisinger's innovation center to develop technologies to predict lower GI and other "high-burden" diseases.
An increased blood-to-stool ratio in the concentration of bacterial short-chain fatty acids marked higher permeability in the intestinal wall.